Biopsy Method and Needle Size on Success of Next-Generation Sequencing in NSCLC: A Brief Report
- PMID: 37090100
- PMCID: PMC10119792
- DOI: 10.1016/j.jtocrr.2023.100497
Biopsy Method and Needle Size on Success of Next-Generation Sequencing in NSCLC: A Brief Report
Abstract
Introduction: Next-generation sequencing (NGS) is essential to the care of patients with NSCLC. Nevertheless, NGS is dependent on adequate material from biopsy. We evaluated the impact of biopsy method and needle gauge necessary for optimizing success in tissue NGS.
Methods: A total of 1660 formalin-fixed, paraffin-embedded samples were submitted to Caris Life Sciences from 2007 to 2022 for tumor profiling. The results of NGS assays were linked with retrospective biopsy data for patients with lung cancer treated at USC/Norris Cancer Center to create a database with the following parameters: demographics, biopsy method, tumor location (lung mass versus lymph node versus metastasis), needle gauge, number of needle passes, complications, tumor volume, DNA content, and status of NGS. Fisher's exact test and analysis of variance were performed to determine the impact of biopsy method and needle gauge (G).
Results: In total, 77 computed tomography (CT)-guided transthoracic core needle (CT-TTCN) biopsies, 74 endobronchial ultrasound (EBUS)-guided transbronchial needle aspirations (TBNAs), 27 bronchial forceps biopsies, and 107 surgical resections were included. Furthermore, 41 of 77 CT-TTCN biopsies (53.2%), 43 of 74 EBUS-TBNAs (58.1%), 22 of 27 bronchial forceps biopsies (81.5%), and 105 of 107 surgical resections (98.1%) underwent successful NGS assays. The probability of successful NGS completion for lung cancers was highest in surgical resections and bronchial forceps biopsies. Needle-based biopsies were more successful when a needle larger than 20G was used. Complication rates were higher for CT-TTCN biopsies compared with EBUS-TBNA (p < 0.0001). Overall, the DNA yield was significantly higher in EBUS-TBNA compared with CT-TTCN biopsies in primary lung sites (p = 0.0002). EBUS-TBNA was found to have higher success rates in NGS compared with CT-TTCN for both primary lung lesions (p = 0.023) and lymph node targets (p = 0.035).
Conclusions: The less invasive EBUS-TBNAs had higher success rates in NGS than CT-TTCN biopsies and resulted in higher DNA concentrations. In CT-TTCN biopsies, use of 20G or smaller needles is associated with a higher risk of obtaining an inadequate specimen regardless of the number of passes taken. Surgical and bronchial forceps biopsies had highest success in achieving NGS.
Keywords: Biopsy method; Fine-needle aspiration; Needle gauge; Next-generation sequencing (NGS); Non–small cell lung cancer (NSCLC); Transthoracic core needle biopsy.
© 2023 The Authors.
Figures

Similar articles
-
The Impact of Core Tissues on Successful Next-Generation Sequencing Analysis of Specimens Obtained through Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration.Cancers (Basel). 2021 Nov 23;13(23):5879. doi: 10.3390/cancers13235879. Cancers (Basel). 2021. PMID: 34884991 Free PMC article.
-
Small lung tumor biopsy samples are feasible for high quality targeted next generation sequencing.Cancer Sci. 2019 Aug;110(8):2652-2657. doi: 10.1111/cas.14112. Epub 2019 Jun 21. Cancer Sci. 2019. PMID: 31222846 Free PMC article.
-
Next-Generation Sequencing Analysis on Image-Guided Biopsy Samples in Early-Stage Lung Cancer: Feasibility Study and Comparison With Surgical Samples.JTO Clin Res Rep. 2024 Dec 11;6(2):100777. doi: 10.1016/j.jtocrr.2024.100777. eCollection 2025 Feb. JTO Clin Res Rep. 2024. PMID: 39877030 Free PMC article.
-
A systematic review and meta-analysis of the adequacy of endobronchial ultrasound transbronchial needle aspiration for next-generation sequencing in patients with non-small cell lung cancer.Lung Cancer. 2022 Apr;166:17-26. doi: 10.1016/j.lungcan.2022.01.018. Epub 2022 Jan 25. Lung Cancer. 2022. PMID: 35151114
-
Comparing diagnostic sensitivity of different needle sizes for lymph nodes suspected of lung cancer in endobronchial ultrasound transbronchial needle aspiration: Systematic review and meta-analysis.Clin Respir J. 2021 Dec;15(12):1328-1336. doi: 10.1111/crj.13436. Epub 2021 Aug 31. Clin Respir J. 2021. PMID: 34402194
Cited by
-
Current challenges and practical aspects of molecular pathology for non-small cell lung cancers.Virchows Arch. 2024 Feb;484(2):233-246. doi: 10.1007/s00428-023-03651-1. Epub 2023 Oct 6. Virchows Arch. 2024. PMID: 37801103 Free PMC article. Review.
-
High-Quality Samples for Next-Generation Sequencing and PD-L1 Assessment in Non-Small Cell Lung Cancer: The Role of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration.Diagnostics (Basel). 2025 Apr 22;15(9):1064. doi: 10.3390/diagnostics15091064. Diagnostics (Basel). 2025. PMID: 40361881 Free PMC article.
-
Homologous recombination deficiency testing in patients with high grade ovarian cancer: factors influencing test success.Future Oncol. 2025 Feb;21(3):341-347. doi: 10.1080/14796694.2024.2433412. Epub 2024 Nov 29. Future Oncol. 2025. PMID: 39611711 Free PMC article.
-
Seize the Opportunity With Small Tissue Samples: The Tailor Teaches!JTO Clin Res Rep. 2023 Mar 24;4(4):100507. doi: 10.1016/j.jtocrr.2023.100507. eCollection 2023 Apr. JTO Clin Res Rep. 2023. PMID: 37101781 Free PMC article. No abstract available.
-
Optimizing Precision: A Trajectory Tract Reference Approach to Minimize Complications in CT-Guided Transthoracic Core Biopsy.Diagnostics (Basel). 2024 Apr 10;14(8):796. doi: 10.3390/diagnostics14080796. Diagnostics (Basel). 2024. PMID: 38667442 Free PMC article.
References
-
- Ettinger D.S., Aisner D.L., Wood D.E., et al. NCCN guidelines insights: non-small cell lung cancer, version 5.2018. J Natl Compr Canc Netw. 2018;16:807–821. - PubMed
-
- Robert N.J., Espirito J.L., Chen L., et al. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in the US Oncology Network. Lung Cancer. 2022;166:197–204. - PubMed
-
- Debora S., Bruno L.M.H., Li X., Su E.W., Zhu Y.E., Patel M. Racial disparities in biomarker testing and clinical trial enrollment in non-small cell lung cancer (NSCLC) J Clin Oncol. 2021;39(suppl 15)
-
- Dupain C., Masliah-Planchon J., Gu C., et al. Fine-needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next-generation sequencing in cancer patients included in the SHIVA02 trial. Mol Oncol. 2021;15:104–115. - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources